Print
Email
Week of April 20 - April 26, 2008
Caprospinol (SP-233) is among six Alzheimer's drugs just chosen for the list of 100 greatest investigational drugs in worldwide development in 2008. Caprospinol is a novel Alzheimer’s drug candidate that has shown numerous properties to indicate it as a promising direct treatment for Alzheimer’s disease.
Caprospinol shows promise in delaying or even halting Alzheimer’s. In animal studies, Caprospinol restored memory, maintained neuronal cell energy levels and protected against future neuronal brain damage. It's owner, Samaritan Pharmaceuticals, is readying the drug for Phase I clinical trials, for which they have already received FDA approval.
Click the triangle to run the video.
Article continues below the video.
Caprospinol clears beta-amyloid plaques from the brain and protect the brain against Beta-Amyloid induced cell death. Caprospinol binds to the Beta-Amyloid peptide, preventing its aggregation into more neurotoxic entities and entry into neurons, as well as protecting neuronal mitochondria from Beta-Amyloid induced damage, and maintaining neuronal cell energy levels.
“Unlike drugs currently used to treat Alzheimer’s that simply alleviate symptoms, Caprospinol has the potential be a viable treatment for the disease itself,” said Dr. Janet Greeson, Chief Executive Officer of Samaritan. “There are more than five million Americans who suffer with this mind robbing disease and the current market is over $4 billion a year, and expected to grow dramatically, with the aging of the baby boomers.”
Caprospinol was cited by R&D Directions’ magazine’s seventh-annual list of 100 greatest investigational drugs in development by large and small companies throughout the world. According to R&D Directions, compounds on this list distinguish themselves as "innovative, first-in-class or clearly advanced compared with those on the market."
Six drugs for Alzheimer’s disease, some also targeting other cognitive disorders, were chosen, including candidates from pharmaceutical giants Wyeth, GlaxoSmithKline, and AstraZeneca.
MORE INFORMATION:
http://www.samaritanpharma.com
SOURCES:
Samaritan Pharmaceuticals, Inc.
BY:
Peter Berger, Alzheimer's Weekly
Reviewed for medical accuracy by
Dr. Boaz Ancselovic, MD, Geriatrician, Alzheimer's Weekly
COPYRIGHT:
Copyright © 2008. Alzheimer's Weekly LLC.
All rights reserved.
« Back
|
